Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | HTR7 | P34969 | 6/20 | 0.47 |
| ▸ | HTR6 | P50406 | 6/20 | 0.47 |
| ▸ | HTR1A | P08908 | 6/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461231 | 1.00 | DRD2 (0.47) | DRD2HTR7HTR6HTR1ASLC6A4 | |
| Sulfuric Acid SCHEMBL9046410 | 0.79 | HTR1A (0.48) | DRD2HTR7HTR6HTR1ASLC6A4 | |
| Sulfuric Acid SCHEMBL30909161 | 0.79 | HTR1A (0.48) | DRD2HTR7HTR6HTR1ASLC6A4 | |
| SCHEMBL9049200 | 0.79 | HTR1A (0.44) | DRD2HTR7HTR6HTR1ASLC6A4 | |
| Oxalic Acid SCHEMBL9047850 | 0.78 | OPRM1 (0.52) | HTR7HTR6HTR1ASLC6A4 | |
| SCHEMBL7455861 | 0.78 | SLC6A4 (0.53) | DRD2HTR7HTR6HTR1ASLC6A4 | |
| SCHEMBL7465697 | 0.77 | KDM4A (0.41) | DRD2HTR7HTR6HTR1ASLC6A4 | |
| SCHEMBL7459958 | 0.75 | HTR1A (0.53) | DRD2HTR7HTR6HTR1ASLC6A4 | |
| Oxalic Acid SCHEMBL9049150 | 0.74 | SLC6A4 (0.51) | DRD2HTR7HTR6HTR1ASLC6A4 | |
| SCHEMBL7454379 | 0.74 | HTR1A (0.44) | DRD2HTR7HTR6HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | DRD2 691/4885HTR7 13/4885HTR6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.